Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2018; Provides Earnings Guidance for the Year Ending March 31, 2019
January 30, 2019 at 01:30 am EST
Share
Japan Tissue Engineering Co., Ltd. reported earnings results for the nine months ended December 31, 2018. For the nine months, the company reported net sales of ¥1,537 million compared to ¥1,609 million a year ago. Operating loss was ¥480 million compared to operating income of ¥121 million a year ago. Net loss was ¥485 million or ¥11.95 per share compared to net income of ¥106 million or ¥2.62 per share a year ago.
The company provided earnings guidance for the year ending March 31, 2019. For the year, the company expects net sales of ¥2,343 million, operating loss of ¥415 million and net loss of ¥413 million or ¥10.18 per share.
Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.
Japan Tissue Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2018; Provides Earnings Guidance for the Year Ending March 31, 2019
JAPAN TISSUE ENGINEERING CO., LTD. 